Immune checkpoint inhibitors and cardiac toxicity: An emerging issue

Current Medicinal Chemistry

Volumn 25, Issue 11, 2018, Pages 1327-1339

  Varricchi, Gilda ^a   Marone, Giancarlo ^a   Mercurio, Valentina ^a,b   Galdiero, Maria Rosaria ^a   Bonaduce, Domenico ^a   Tocchetti, Carlo G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Cancer; Cardiac toxicity; Checkpoints; CTLA 4; Melanoma; Myocarditis; PD 1; PD L1

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; BMS 946559; BTLA ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; IMMUNE CHECKPOINT INHIBITOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IPILIMUMAB; LAG 3 ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TIGIT ANTIBODY; TIM 3 ANTIBODY; UNCLASSIFIED DRUG; VISTA ANTIBODY; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CARDIOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HEART FAILURE; HUMAN; MELANOMA; MOUSE; MYOCARDITIS; NONHUMAN; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOMYOPATHY; CHEMICALLY INDUCED; IMMUNOTHERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARDIOMYOPATHIES; CARDIOTOXICITY; COSTIMULATORY AND INHIBITORY T-CELL RECEPTORS; HUMANS; IMMUNOTHERAPY; MELANOMA;

EID: 85047796335     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867324666170407125017     Document Type: Review

References (114)

1. Zamorano, J.L.; Lancellotti, P.; Rodriguez Muñoz, D.; Aboyans, V.; Asteggiano, R.; Galderisi, M.; Habib, G.; Lenihan, D.J.; Lip, G.Y.; Lyon, A.R.; Lopez Fernandez, T.; Mohty, D.; Piepoli, M.F.; Tamargo, J.; Torbicki, A.; Suter, T.M. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur. Heart J., 2016, 37(36), 2768-2801.
2. Ky, B.; Vejpongsa, P.; Yeh, E.T.; Force, T.; Moslehi, J.J. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ. Res., 2013, 113(6), 754-764.
3. Bloom, M.W.; Hamo, C.E.; Cardinale, D.; Ky, B.; Nohria, A.; Baer, L.; Skopicki, H.; Lenihan, D.J.; Gheorghiade, M.; Lyon, A.R.; Butler, J. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. Circ. Heart Fail, 2016, 9(1), e002661.
4. Moslehi, J.J. Cardiovascular Toxic Effects of Targeted Cancer Therapies. N. Engl. J. Med., 2016, 375(15), 1457-1467.
5. Suter, T.M.; Ewer, M.S. Cancer drugs and the heart: importance and management. Eur. Heart J., 2013, 34(15), 1102-1111.
6. Pitt, J.M.; Vétizou, M.; Daillère, R.; Roberti, M.P.; Yamazaki, T.; Routy, B.; Lepage, P.; Boneca, I.G.; Chamaillard, M.; Kroemer, G.; Zitvogel, L. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and-Extrinsic Factors. Immunity, 2016, 44(6), 1255-1269.
7. Hurst, J.H. Cancer immunotherapy innovator James Allison receives the 2015 Lasker~DeBakey Clinical Medical Research Award. J. Clin. Invest., 2015, 125(10), 3732-3736.
8. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; Leming, P.D.; Spigel, D.R.; Antonia, S.J.; Horn, L.; Drake, C.G.; Pardoll, D.M.; Chen, L.; Sharfman, W.H.; Anders, R.A.; Taube, J.M.; McMiller, T.L.; Xu, H.; Korman, A.J.; Jure-Kunkel, M.; Agrawal, S.; McDonald, D.; Kollia, G.D.; Gupta, A.; Wigginton, J.M.; Sznol, M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med., 2012, 366(26), 2443-2454.
9. Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; Pitot, H.C.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton, K.; Chen, S.; Salay, T.M.; Alaparthy, S.; Grosso, J.F.; Korman, A.J.; Parker, S.M.; Agrawal, S.; Goldberg, S.M.; Pardoll, D.M.; Gupta, A.; Wigginton, J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med., 2012, 366(26), 2455-2465.
10. Powles, T.; Eder, J.P.; Fine, G.D.; Braiteh, F.S.; Loriot, Y.; Cruz, C.; Bellmunt, J.; Burris, H.A.; Petrylak, D.P.; Teng, S.L.; Shen, X.; Boyd, Z.; Hegde, P.S.; Chen, D.S.; Vogelzang, N.J. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 2014, 515(7528), 558-562.
11. Herbst, R.S.; Soria, J.C.; Kowanetz, M.; Fine, G.D.; Hamid, O.; Gordon, M.S.; Sosman, J.A.; McDermott, D.F.; Powderly, J.D.; Gettinger, S.N.; Kohrt, H.E.; Horn, L.; Lawrence, D.P.; Rost, S.; Leabman, M.; Xiao, Y.; Mokatrin, A.; Koeppen, H.; Hegde, P.S.; Mellman, I.; Chen, D.S.; Hodi, F.S. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014, 515(7528), 563-567.
12. Tumeh, P.C.; Harview, C.L.; Yearley, J.H.; Shintaku, I.P.; Taylor, E.J.; Robert, L.; Chmielowski, B.; Spasic, M.; Henry, G.; Ciobanu, V.; West, A.N.; Carmona, M.; Kivork, C.; Seja, E.; Cherry, G.; Gutierrez, A.J.; Grogan, T.R.; Mateus, C.; Tomasic, G.; Glaspy, J.A.; Emerson, R.O.; Robins, H.; Pierce, R.H.; Elashoff, D.A.; Robert, C.; Ribas, A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature, 2014, 515(7528), 568-571.
13. Robert, C.; Ribas, A.; Wolchok, J.D.; Hodi, F.S.; Hamid, O.; Kefford, R.; Weber, J.S.; Joshua, A.M.; Hwu, W.J.; Gangadhar, T.C.; Patnaik, A.; Dronca, R.; Zarour, H.; Joseph, R.W.; Boasberg, P.; Chmielowski, B.; Mateus, C.; Postow, M.A.; Gergich, K.; Elassaiss-Schaap, J.; Li, X.N.; Iannone, R.; Ebbinghaus, S.W.; Kang, S.P.; Daud, A. Anti programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet, 2014, 384(9948), 1109-1117.
14. Brahmer, J.; Reckamp, K.L.; Baas, P.; Crinò, L.; Eberhardt, W.E.; Poddubskaya, E.; Antonia, S.; Pluzanski, A.; Vokes, E.E.; Holgado, E.; Waterhouse, D.; Ready, N.; Gainor, J.; Arén Frontera, O.; Havel, L.; Steins, M.; Garassino, M.C.; Aerts, J.G.; Domine, M.; Paz-Ares, L.; Reck, M.; Baudelet, C.; Harbison, C.T.; Lestini, B.; Spigel, D.R. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med., 2015, 373(2), 123-135.
15. Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; Barlesi, F.; Kohlhäufl, M.; Arrieta, O.; Burgio, M.A.; Fayette, J.; Lena, H.; Poddubskaya, E.; Gerber, D.E.; Gettinger, S.N.; Rudin, C.M.; Rizvi, N.; Crinò, L.; Blumenschein, G.R., Jr; Antonia, S.J.; Dorange, C.; Harbison, C.T.; Graf Finckenstein, F.; Brahmer, J.R. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med., 2015, 373(17), 1627-1639.
16. Nghiem, P.T.; Bhatia, S.; Lipson, E.J.; Kudchadkar, R.R.; Miller, N.J.; Annamalai, L.; Berry, S.; Chartash, E.K.; Daud, A.; Fling, S.P.; Friedlander, P.A.; Kluger, H.M.; Kohrt, H.E.; Lundgren, L.; Margolin, K.; Mitchell, A.; Olencki, T.; Pardoll, D.M.; Reddy, S.A.; Shantha, E.M.; Sharfman, W.H.; Sharon, E.; Shemanski, L.R.; Shinohara, M.M.; Sunshine, J.C.; Taube, J.M.; Thompson, J.A.; Townson, S.M.; Yearley, J.H.; Topalian, S.L.; Cheever, M.A. PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N. Engl. J. Med., 2016, 374(26), 2542-2552.
17. Herbst, R.S.; Baas, P.; Kim, D.W.; Felip, E.; Pérez-Gracia, J.L.; Han, J.Y.; Molina, J.; Kim, J.H.; Arvis, C.D.; Ahn, M.J.; Majem, M.; Fidler, M.J.; de Castro, G., Jr; Garrido, M.; Lubiniecki, G.M.; Shentu, Y.; Im, E.; Dolled-Filhart, M.; Garon, E.B. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 2016, 387(10027), 1540-1550.
18. Fehrenbacher, L.; Spira, A.; Ballinger, M.; Kowanetz, M.; Vansteenkiste, J.; Mazieres, J.; Park, K.; Smith, D.; Artal-Cortes, A.; Lewanski, C.; Braiteh, F.; Waterkamp, D.; He, P.; Zou, W.; Chen, D.S.; Yi, J.; Sandler, A.; Rittmeyer, A. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, 2016, 387(10030), 1837-1846.
19. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell, 2011, 144(5), 646-674.
20. Joyce, J.A.; Fearon, D.T. T cell exclusion, immune privilege, and the tumor microenvironment. Science, 2015, 348(6230), 74-80.
21. Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: integrating immunitys roles in cancer suppression and promotion. Science, 2011, 331(6024), 1565-1570.
22. Nguyen, L.T.; Ohashi, P.S. Clinical blockade of PD1 and LAG3potential mechanisms of action. Nat. Rev. Immunol., 2015, 15(1), 45-56.
23. Sharma, P.; Allison, J.P. The future of immune checkpoint therapy. Science, 2015, 348(6230), 56-61.
24. Le Mercier, I.; Lines, J.L.; Noelle, R.J. Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators. Front. Immunol., 2015, 6, 418.
25. Chen, L.; Han, X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest., 2015, 125(9), 3384-3391.
26. Goodman, A.; Patel, S.P.; Kurzrock, R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat. Rev. Clin. Oncol., 2017, 14(4), 203-220.
27. Brunet, J.F.; Denizot, F.; Luciani, M.F.; Roux-Dosseto, M.; Suzan, M.; Mattei, M.G.; Golstein, P. A new member of the immunoglobulin superfamilyCTLA-4. Nature, 1987, 328(6127), 267-270.
28. Linsley, P.S.; Brady, W.; Urnes, M.; Grosmaire, L.S.; Damle, N.K.; Ledbetter, J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med., 1991, 174(3), 561-569.
29. Martin, P.J.; Ledbetter, J.A.; Morishita, Y.; June, C.H.; Beatty, P.G.; Hansen, J.A. A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes. J. Immunol., 1986, 136(9), 3282-3287.
30. Hathcock, K.S.; Laszlo, G.; Dickler, H.B.; Bradshaw, J.; Linsley, P.; Hodes, R.J. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science, 1993, 262(5135), 905-907.
31. Freeman, G.J.; Gribben, J.G.; Boussiotis, V.A.; Ng, J.W.; Restivo, V.A., Jr; Lombard, L.A.; Gray, G.S.; Nadler, L.M. Cloning of B72: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science, 1993, 262(5135), 909-911.
32. Azuma, M.; Ito, D.; Yagita, H.; Okumura, K.; Phillips, J.H.; Lanier, L.L.; Somoza, C. B70 antigen is a second ligand for CTLA-4 and CD28. Nature, 1993, 366(6450), 76-79.
33. Linsley, P.S.; Clark, E.A.; Ledbetter, J.A. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc. Natl. Acad. Sci. USA, 1990, 87(13), 5031-5035.
34. Tivol, E.A.; Borriello, F.; Schweitzer, A.N.; Lynch, W.P.; Bluestone, J.A.; Sharpe, A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity, 1995, 3(5), 541-547.
35. Waterhouse, P.; Penninger, J.M.; Timms, E.; Wakeham, A.; Shahinian, A.; Lee, K.P.; Thompson, C.B.; Griesser, H.; Mak, T.W. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science, 1995, 270(5238), 985-988.
36. Wing, K.; Onishi, Y.; Prieto-Martin, P.; Yamaguchi, T.; Miyara, M.; Fehervari, Z.; Nomura, T.; Sakaguchi, S. CTLA-4 control over Foxp3+ regulatory T cell function. Science, 2008, 322(5899), 271-275.
37. Peggs, K.S.; Quezada, S.A.; Chambers, C.A.; Korman, A.J.; Allison, J.P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med., 2009, 206(8), 1717-1725.
38. Leach, D.R.; Krummel, M.F.; Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science, 1996, 271(5256), 1734-1736.
39. Nishimura, H.; Nose, M.; Hiai, H.; Minato, N.; Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity, 1999, 11(2), 141-151.
40. Nishimura, H.; Okazaki, T.; Tanaka, Y.; Nakatani, K.; Hara, M.; Matsumori, A.; Sasayama, S.; Mizoguchi, A.; Hiai, H.; Minato, N.; Honjo, T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science, 2001, 291(5502), 319-322.
41. Boussiotis, V.A. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N. Engl. J. Med., 2016, 375(18), 1767-1778.
42. Okazaki, T.; Honjo, T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol., 2007, 19(7), 813-824.
43. Baban, B.; Liu, J.Y.; Qin, X.; Weintraub, N.L.; Mozaffari, M.S. Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153. PLoS One, 2015, 10(4), e0124059.
44. Freeman, G.J.; Long, A.J.; Iwai, Y.; Bourque, K.; Chernova, T.; Nishimura, H.; Fitz, L.J.; Malenkovich, N.; Okazaki, T.; Byrne, M.C.; Horton, H.F.; Fouser, L.; Carter, L.; Ling, V.; Bowman, M.R.; Carreno, B.M.; Collins, M.; Wood, C.R.; Honjo, T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med., 2000, 192(7), 1027-1034.
45. Yokosuka, T.; Takamatsu, M.; Kobayashi-Imanishi, W.; Hashimoto-Tane, A.; Azuma, M.; Saito, T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med., 2012, 209(6), 1201-1217.
46. Sheppard, K.A.; Fitz, L.J.; Lee, J.M.; Benander, C.; George, J.A.; Wooters, J.; Qiu, Y.; Jussif, J.M.; Carter, L.L.; Wood, C.R.; Chaudhary, D. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett., 2004, 574(1-3), 37-41.
47. Patsoukis, N.; Bardhan, K.; Chatterjee, P.; Sari, D.; Liu, B.; Bell, L.N.; Karoly, E.D.; Freeman, G.J.; Petkova, V.; Seth, P.; Li, L.; Boussiotis, V.A. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun., 2015, 6, 6692.
48. Francisco, L.M.; Sage, P.T.; Sharpe, A.H. The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev., 2010, 236, 219-242.
49. Dong, H.; Strome, S.E.; Salomao, D.R.; Tamura, H.; Hirano, F.; Flies, D.B.; Roche, P.C.; Lu, J.; Zhu, G.; Tamada, K.; Lennon, V.A.; Celis, E.; Chen, L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med., 2002, 8(8), 793-800.
50. Ferrari, R.; Bachetti, T.; Confortini, R.; Opasich, C.; Febo, O.; Corti, A.; Cassani, G.; Visioli, O. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation, 1995, 92(6), 1479-1486.
51. Cavalli, G.; Pappalardo, F.; Mangieri, A.; Dinarello, C.A.; Dagna, L.; Tresoldi, M. Treating Life-Threatening Myocarditis by Blocking Interleukin-1. Crit. Care Med., 2016, 44(8), e751-e754.
52. Latchman, Y.; Wood, C.R.; Chernova, T.; Chaudhary, D.; Borde, M.; Chernova, I.; Iwai, Y.; Long, A.J.; Brown, J.A.; Nunes, R.; Greenfield, E.A.; Bourque, K.; Boussiotis, V.A.; Carter, L.L.; Carreno, B.M.; Malenkovich, N.; Nishimura, H.; Okazaki, T.; Honjo, T.; Sharpe, A.H.; Freeman, G.J. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol., 2001, 2(3), 261-268.
53. Iwai, Y.; Ishida, M.; Tanaka, Y.; Okazaki, T.; Honjo, T.; Minato, N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA, 2002, 99(19), 12293-12297.
54. Azuma, T.; Yao, S.; Zhu, G.; Flies, A.S.; Flies, S.J.; Chen, L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood, 2008, 111(7), 3635-3643.
55. Chen, J.; Jiang, C.C.; Jin, L.; Zhang, X.D. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann. Oncol., 2016, 27(3), 409-416.
56. Zou, W.; Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol., 2008, 8(6), 467-477.
57. Rizvi, N.A.; Hellmann, M.D.; Snyder, A.; Kvistborg, P.; Makarov, V.; Havel, J.J.; Lee, W.; Yuan, J.; Wong, P.; Ho, T.S.; Miller, M.L.; Rekhtman, N.; Moreira, A.L.; Ibrahim, F.; Bruggeman, C.; Gasmi, B.; Zappasodi, R.; Maeda, Y.; Sander, C.; Garon, E.B.; Merghoub, T.; Wolchok, J.D.; Schumacher, T.N.; Chan, T.A. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 2015, 348(6230), 124-128.
58. Ribas, A.; Shin, D.S.; Zaretsky, J.; Frederiksen, J.; Cornish, A.; Avramis, E.; Seja, E.; Kivork, C.; Siebert, J.; Kaplan-Lefko, P.; Wang, X.; Chmielowski, B.; Glaspy, J.A.; Tumeh, P.C.; Chodon, T.; Peer, D.; Comin-Anduix, B. PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol. Res., 2016, 4(3), 194-203.
59. Brahmer, J.R.; Drake, C.G.; Wollner, I.; Powderly, J.D.; Picus, J.; Sharfman, W.H.; Stankevich, E.; Pons, A.; Salay, T.M.; McMiller, T.L.; Gilson, M.M.; Wang, C.; Selby, M.; Taube, J.M.; Anders, R.; Chen, L.; Korman, A.J.; Pardoll, D.M.; Lowy, I.; Topalian, S.L. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol., 2010, 28(19), 3167-3175.
60. Topalian, S.L.; Sznol, M.; McDermott, D.F.; Kluger, H.M.; Carvajal, R.D.; Sharfman, W.H.; Brahmer, J.R.; Lawrence, D.P.; Atkins, M.B.; Powderly, J.D.; Leming, P.D.; Lipson, E.J.; Puzanov, I.; Smith, D.C.; Taube, J.M.; Wigginton, J.M.; Kollia, G.D.; Gupta, A.; Pardoll, D.M.; Sosman, J.A.; Hodi, F.S. Survival, durable tumor remission, and longterm safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol., 2014, 32(10), 1020-1030.
61. Robert, C.; Long, G.V.; Brady, B.; Dutriaux, C.; Maio, M.; Mortier, L.; Hassel, J.C.; Rutkowski, P.; McNeil, C.; Kalinka-Warzocha, E.; Savage, K.J.; Hernberg, M.M.; Lebbé, C.; Charles, J.; Mihalcioiu, C.; Chiarion-Sileni, V.; Mauch, C.; Cognetti, F.; Arance, A.; Schmidt, H.; Schadendorf, D.; Gogas, H.; Lundgren-Eriksson, L.; Horak, C.; Sharkey, B.; Waxman, I.M.; Atkinson, V.; Ascierto, P.A. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med., 2015, 372(4), 320-330.
62. Hamid, O.; Robert, C.; Daud, A.; Hodi, F.S.; Hwu, W.J.; Kefford, R.; Wolchok, J.D.; Hersey, P.; Joseph, R.W.; Weber, J.S.; Dronca, R.; Gangadhar, T.C.; Patnaik, A.; Zarour, H.; Joshua, A.M.; Gergich, K.; Elassaiss-Schaap, J.; Algazi, A.; Mateus, C.; Boasberg, P.; Tumeh, P.C.; Chmielowski, B.; Ebbinghaus, S.W.; Li, X.N.; Kang, S.P.; Ribas, A. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med., 2013, 369(2), 134-144.
63. Westin, J.R.; Chu, F.; Zhang, M.; Fayad, L.E.; Kwak, L.W.; Fowler, N.; Romaguera, J.; Hagemeister, F.; Fanale, M.; Samaniego, F.; Feng, L.; Baladandayuthapani, V.; Wang, Z.; Ma, W.; Gao, Y.; Wallace, M.; Vence, L.M.; Radvanyi, L.; Muzzafar, T.; Rotem-Yehudar, R.; Davis, R.E.; Neelapu, S.S. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol., 2014, 15(1), 69-77.
64. Hamanishi, J.; Mandai, M.; Ikeda, T.; Minami, M.; Kawaguchi, A.; Murayama, T.; Kanai, M.; Mori, Y.; Matsumoto, S.; Chikuma, S.; Matsumura, N.; Abiko, K.; Baba, T.; Yamaguchi, K.; Ueda, A.; Hosoe, Y.; Morita, S.; Yokode, M.; Shimizu, A.; Honjo, T.; Konishi, I. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J. Clin. Oncol., 2015, 33(34), 4015-4022.
65. Boutros, C.; Tarhini, A.; Routier, E.; Lambotte, O.; Ladurie, F.L.; Carbonnel, F.; Izzeddine, H.; Marabelle, A.; Champiat, S.; Berdelou, A.; Lanoy, E.; Texier, M.; Libenciuc, C.; Eggermont, A.M.; Soria, J.C.; Mateus, C.; Robert, C. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol., 2016, 13(8), 473-486.
66. Sakuishi, K.; Ngiow, S.F.; Sullivan, J.M.; Teng, M.W.; Kuchroo, V.K.; Smyth, M.J.; Anderson, A.C. TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. OncoImmunology, 2013, 2(4), e23849.
67. Yan, J.; Zhang, Y.; Zhang, J.P.; Liang, J.; Li, L.; Zheng, L. Tim-3 expression defines regulatory T cells in human tumors. PLoS One, 2013, 8(3), e58006.
68. Huang, C.T.; Workman, C.J.; Flies, D.; Pan, X.; Marson, A.L.; Zhou, G.; Hipkiss, E.L.; Ravi, S.; Kowalski, J.; Levitsky, H.I.; Powell, J.D.; Pardoll, D.M.; Drake, C.G.; Vignali, D.A. Role of LAG-3 in regulatory T cells. Immunity, 2004, 21(4), 503-513.
69. Gagliani, N.; Magnani, C.F.; Huber, S.; Gianolini, M.E.; Pala, M.; Licona-Limon, P.; Guo, B.; Herbert, D.R.; Bulfone, A.; Trentini, F.; Di Serio, C.; Bacchetta, R.; Andreani, M.; Brockmann, L.; Gregori, S.; Flavell, R.A.; Roncarolo, M.G. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat. Med., 2013, 19(6), 739-746.
70. Okamura, T.; Fujio, K.; Shibuya, M.; Sumitomo, S.; Shoda, H.; Sakaguchi, S.; Yamamoto, K. CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2. Proc. Natl. Acad. Sci. USA, 2009, 106(33), 13974-13979.
71. Matsuzaki, J.; Gnjatic, S.; Mhawech-Fauceglia, P.; Beck, A.; Miller, A.; Tsuji, T.; Eppolito, C.; Qian, F.; Lele, S.; Shrikant, P.; Old, L.J.; Odunsi, K. Tumor-infiltrating NYESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. USA, 2010, 107(17), 7875-7880.
72. Woo, S.R.; Turnis, M.E.; Goldberg, M.V.; Bankoti, J.; Selby, M.; Nirschl, C.J.; Bettini, M.L.; Gravano, D.M.; Vogel, P.; Liu, C.L.; Tangsombatvisit, S.; Grosso, J.F.; Netto, G.; Smeltzer, M.P.; Chaux, A.; Utz, P.J.; Workman, C.J.; Pardoll, D.M.; Korman, A.J.; Drake, C.G.; Vignali, D.A. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res., 2012, 72(4), 917-927.
73. Yu, X.; Harden, K.; Gonzalez, L.C.; Francesco, M.; Chiang, E.; Irving, B.; Tom, I.; Ivelja, S.; Refino, C.J.; Clark, H.; Eaton, D.; Grogan, J.L. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol., 2009, 10(1), 48-57.
74. Stanietsky, N.; Simic, H.; Arapovic, J.; Toporik, A.; Levy, O.; Novik, A.; Levine, Z.; Beiman, M.; Dassa, L.; Achdout, H.; Stern-Ginossar, N.; Tsukerman, P.; Jonjic, S.; Mandelboim, O. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc. Natl. Acad. Sci. USA, 2009, 106(42), 17858-17863.
75. Johnston, R.J.; Comps-Agrar, L.; Hackney, J.; Yu, X.; Huseni, M.; Yang, Y.; Park, S.; Javinal, V.; Chiu, H.; Irving, B.; Eaton, D.L.; Grogan, J.L. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell, 2014, 26(6), 923-937.
76. Watanabe, N.; Gavrieli, M.; Sedy, J.R.; Yang, J.; Fallarino, F.; Loftin, S.K.; Hurchla, M.A.; Zimmerman, N.; Sim, J.; Zang, X.; Murphy, T.L.; Russell, J.H.; Allison, J.P.; Murphy, K.M. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol., 2003, 4(7), 670-679.
77. Han, P.; Goularte, O.D.; Rufner, K.; Wilkinson, B.; Kaye, J. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J. Immunol., 2004, 172(10), 5931-5939.
78. Lasaro, M.O.; Sazanovich, M.; Giles-Davis, W.; Mrass, P.; Bunte, R.M.; Sewell, D.A.; Hussain, S.F.; Fu, Y.X.; Weninger, W.; Paterson, Y.; Ertl, H.C. Active immunotherapy combined with blockade of a coinhibitory pathway achieves regression of large tumor masses in cancer-prone mice. Mol. Ther., 2011, 19(9), 1727-1736.
79. Lines, J.L.; Pantazi, E.; Mak, J.; Sempere, L.F.; Wang, L.; OConnell, S.; Ceeraz, S.; Suriawinata, A.A.; Yan, S.; Ernstoff, M.S.; Noelle, R. VISTA is an immune checkpoint molecule for human T cells. Cancer Res., 2014, 74(7), 1924-1932.
80. Le Mercier, I.; Chen, W.; Lines, J.L.; Day, M.; Li, J.; Sergent, P.; Noelle, R.J.; Wang, L. VISTA Regulates the Development of Protective Antitumor Immunity. Cancer Res., 2014, 74(7), 1933-1944.
81. Gangadhar, T.C.; Vonderheide, R.H. Mitigating the toxic effects of anticancer immunotherapy. Nat. Rev. Clin. Oncol., 2014, 11(2), 91-99.
82. Michot, J.M.; Bigenwald, C.; Champiat, S.; Collins, M.; Carbonnel, F.; Postel-Vinay, S.; Berdelou, A.; Varga, A.; Bahleda, R.; Hollebecque, A.; Massard, C.; Fuerea, A.; Ribrag, V.; Gazzah, A.; Armand, J.P.; Amellal, N.; Angevin, E.; Noel, N.; Boutros, C.; Mateus, C.; Robert, C.; Soria, J.C.; Marabelle, A.; Lambotte, O. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer, 2016, 54, 139-148.
83. Buchbinder, E.I.; Desai, A. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. Am. J. Clin. Oncol., 2016, 39(1), 98-106.
84. Hodi, F.S.; ODay, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; Akerley, W.; van den Eertwegh, A.J.; Lutzky, J.; Lorigan, P.; Vaubel, J.M.; Linette, G.P.; Hogg, D.; Ottensmeier, C.H.; Lebbé, C.; Peschel, C.; Quirt, I.; Clark, J.I.; Wolchok, J.D.; Weber, J.S.; Tian, J.; Yellin, M.J.; Nichol, G.M.; Hoos, A.; Urba, W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med., 2010, 363(8), 711-723.
85. Robert, C.; Thomas, L.; Bondarenko, I.; ODay, S.; Weber, J.; Garbe, C.; Lebbe, C.; Baurain, J.F.; Testori, A.; Grob, J.J.; Davidson, N.; Richards, J.; Maio, M.; Hauschild, A.; Miller, W.H., Jr; Gascon, P.; Lotem, M.; Harmankaya, K.; Ibrahim, R.; Francis, S.; Chen, T.T.; Humphrey, R.; Hoos, A.; Wolchok, J.D. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med., 2011, 364(26), 2517-2526.
86. Lacouture, M.E.; Wolchok, J.D.; Yosipovitch, G.; Kähler, K.C.; Busam, K.J.; Hauschild, A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J. Am. Acad. Dermatol., 2014, 71(1), 161-169.
87. Weber, J.S.; Kähler, K.C.; Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol., 2012, 30(21), 2691-2697.
88. Corsello, S.M.; Barnabei, A.; Marchetti, P.; De Vecchis, L.; Salvatori, R.; Torino, F. Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab., 2013, 98(4), 1361-1375.
89. Keir, M.E.; Liang, S.C.; Guleria, I.; Latchman, Y.E.; Qipo, A.; Albacker, L.A.; Koulmanda, M.; Freeman, G.J.; Sayegh, M.H.; Sharpe, A.H. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med., 2006, 203(4), 883-895.
90. Costa, R.; Carneiro, B.A.; Agulnik, M.; Rademaker, A.W.; Pai, S.G.; Villaflor, V.M.; Cristofanilli, M.; Sosman, J.A.; Giles, F.J. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials. Oncotarget, 2016.
91. Eigentler, T.K.; Hassel, J.C.; Berking, C.; Aberle, J.; Bachmann, O.; Grünwald, V.; Kähler, K.C.; Loquai, C.; Reinmuth, N.; Steins, M.; Zimmer, L.; Sendl, A.; Gutzmer, R. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat. Rev., 2016, 45, 7-18.
92. Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Schadendorf, D.; Dummer, R.; Smylie, M.; Rutkowski, P.; Ferrucci, P.F.; Hill, A.; Wagstaff, J.; Carlino, M.S.; Haanen, J.B.; Maio, M.; Marquez-Rodas, I.; McArthur, G.A.; Ascierto, P.A.; Long, G.V.; Callahan, M.K.; Postow, M.A.; Grossmann, K.; Sznol, M.; Dreno, B.; Bastholt, L.; Yang, A.; Rollin, L.M.; Horak, C.; Hodi, F.S.; Wolchok, J.D. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med., 2015, 373(1), 23-34.
93. Postow, M.A.; Chesney, J.; Pavlick, A.C.; Robert, C.; Grossmann, K.; McDermott, D.; Linette, G.P.; Meyer, N.; Giguere, J.K.; Agarwala, S.S.; Shaheen, M.; Ernstoff, M.S.; Minor, D.; Salama, A.K.; Taylor, M.; Ott, P.A.; Rollin, L.M.; Horak, C.; Gagnier, P.; Wolchok, J.D.; Hodi, F.S. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med., 2015, 372(21), 2006-2017.
94. Wolchok, J.D.; Kluger, H.; Callahan, M.K.; Postow, M.A.; Rizvi, N.A.; Lesokhin, A.M.; Segal, N.H.; Ariyan, C.E.; Gordon, R.A.; Reed, K.; Burke, M.M.; Caldwell, A.; Kronenberg, S.A.; Agunwamba, B.U.; Zhang, X.; Lowy, I.; Inzunza, H.D.; Feely, W.; Horak, C.E.; Hong, Q.; Korman, A.J.; Wigginton, J.M.; Gupta, A.; Sznol, M. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med., 2013, 369(2), 122-133.
95. Naidoo, J.; Page, D.B.; Li, B.T.; Connell, L.C.; Schindler, K.; Lacouture, M.E.; Postow, M.A.; Wolchok, J.D. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol., 2015, 26(12), 2375-2391.
96. Love, V.A.; Grabie, N.; Duramad, P.; Stavrakis, G.; Sharpe, A.; Lichtman, A. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ. Res., 2007, 101(3), 248-257.
97. Voskens, C.J.; Goldinger, S.M.; Loquai, C.; Robert, C.; Kaehler, K.C.; Berking, C.; Bergmann, T.; Bockmeyer, C.L.; Eigentler, T.; Fluck, M.; Garbe, C.; Gutzmer, R.; Grabbe, S.; Hauschild, A.; Hein, R.; Hundorfean, G.; Justich, A.; Keller, U.; Klein, C.; Mateus, C.; Mohr, P.; Paetzold, S.; Satzger, I.; Schadendorf, D.; Schlaeppi, M.; Schuler, G.; Schuler-Thurner, B.; Trefzer, U.; Ulrich, J.; Vaubel, J.; von Moos, R.; Weder, P.; Wilhelm, T.; Göppner, D.; Dummer, R.; Heinzerling, L.M. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One, 2013, 8(1), e53745.
98. Läubli, H.; Balmelli, C.; Bossard, M.; Pfister, O.; Glatz, K.; Zippelius, A. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J. Immunother. Cancer, 2015, 3, 11.
99. Geisler, B.P.; Raad, R.A.; Esaian, D.; Sharon, E.; Schwartz, D.R. Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. J. Immunother. Cancer, 2015, 3, 4.
100. Yun, S.; Vincelette, N. D.; Mansour, I.; Hariri, D.; Motamed, S. Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case. Rep. Oncol. Med., 2015, 2015, 794842.
101. Heinzerling, L.; Ott, P.A.; Hodi, F.S.; Husain, A.N.; Tajmir-Riahi, A.; Tawbi, H.; Pauschinger, M.; Gajewski, T.F.; Lipson, E.J.; Luke, J.J. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J. Immunother. Cancer, 2016, 4, 50.
102. Johnson, D.B.; Balko, J.M.; Compton, M.L.; Chalkias, S.; Gorham, J.; Xu, Y.; Hicks, M.; Puzanov, I.; Alexander, M.R.; Bloomer, T.L.; Becker, J.R.; Slosky, D.A.; Phillips, E.J.; Pilkinton, M.A.; Craig-Owens, L.; Kola, N.; Plautz, G.; Reshef, D.S.; Deutsch, J.S.; Deering, R.P.; Olenchock, B.A.; Lichtman, A.H.; Roden, D.M.; Seidman, C.E.; Koralnik, I.J.; Seidman, J.G.; Hoffman, R.D.; Taube, J.M.; Diaz, L.A., Jr; Anders, R.A.; Sosman, J.A.; Moslehi, J.J. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N. Engl. J. Med., 2016, 375(18), 1749-1755.
103. Novo, G.; Cadeddu, C.; Sucato, V.; Pagliaro, P.; Romano, S.; Tocchetti, C. G.; Zito, C.; Longobardo, L.; Nodari, S.; Penco, M. Role of biomarkers in monitoring antiblastic cardiotoxicity. J. Cardiovasc. Med. (Hagerstown), 2016, 17(Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection), e27-e34.
104. Caio, G.; Volta, U.; Cerrato, E.; Clavenzani, P.; Montali, N.; Cogliandro, R.; Stanghellini, V.; Golzio, P.G.; Gaita, F.; Farrugia, G.; De Giorgio, R. Detection of anticonductive tissue autoantibodies in a patient with chronic intestinal pseudo-obstruction and sick sinus syndrome. Eur. J. Gastroenterol. Hepatol., 2013, 25(11), 1358-1363.
105. Caio, G. Myocarditis with Immune Checkpoint Blockade. N. Engl. J. Med., 2017, 376(3), 291-292.
106. Grabie, N.; Gotsman, I.; DaCosta, R.; Pang, H.; Stavrakis, G.; Butte, M.J.; Keir, M.E.; Freeman, G.J.; Sharpe, A.H.; Lichtman, A.H. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation, 2007, 116(18), 2062-2071.
107. Okazaki, T.; Tanaka, Y.; Nishio, R.; Mitsuiye, T.; Mizoguchi, A.; Wang, J.; Ishida, M.; Hiai, H.; Matsumori, A.; Minato, N.; Honjo, T. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med., 2003, 9(12), 1477-1483.
108. Tarrio, M.L.; Grabie, N.; Bu, D.X.; Sharpe, A.H.; Lichtman, A.H. PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J. Immunol., 2012, 188(10), 4876-4884.
109. Lucas, J.A.; Menke, J.; Rabacal, W.A.; Schoen, F.J.; Sharpe, A.H.; Kelley, V.R. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J. Immunol., 2008, 181(4), 2513-2521.
110. Wang, J.; Okazaki, I.M.; Yoshida, T.; Chikuma, S.; Kato, Y.; Nakaki, F.; Hiai, H.; Honjo, T.; Okazaki, T. PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int. Immunol., 2010, 22(6), 443-452.
111. Prashanth, P.; Grant, A.M.; Atkinson, V.; Parente, P.; Andrews, M.C.; Parakh, S.; Cebon, J.S.; Klein, O. 33 (suppl.), abstr9059. 2015 ASCO Annual Meeting, 2015.
112. Douglas, B. J.; Nikhil, I. K.; Puzanov, I.; Mudigonda, T.; Kaufman, H.; Sosman, J. A.; Mehnert, J. M.; Clark, J. Ipilimumab in metastatic melanoma patients with preexisting autoimmune disorders. J. Clin. Oncol., 2015, 33(suppl.), 9019.
113. Vétizou, M.; Pitt, J.M.; Daillère, R.; Lepage, P.; Waldschmitt, N.; Flament, C.; Rusakiewicz, S.; Routy, B.; Roberti, M.P.; Duong, C.P.; Poirier-Colame, V.; Roux, A.; Becharef, S.; Formenti, S.; Golden, E.; Cording, S.; Eberl, G.; Schlitzer, A.; Ginhoux, F.; Mani, S.; Yamazaki, T.; Jacquelot, N.; Enot, D.P.; Bérard, M.; Nigou, J.; Opolon, P.; Eggermont, A.; Woerther, P.L.; Chachaty, E.; Chaput, N.; Robert, C.; Mateus, C.; Kroemer, G.; Raoult, D.; Boneca, I.G.; Carbonnel, F.; Chamaillard, M.; Zitvogel, L. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science, 2015, 350(6264), 1079-1084.
114. Sivan, A.; Corrales, L.; Hubert, N.; Williams, J.B.; Aquino-Michaels, K.; Earley, Z.M.; Benyamin, F.W.; Lei, Y.M.; Jabri, B.; Alegre, M.L.; Chang, E.B.; Gajewski, T.F. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science, 2015, 350(6264), 1084-1089.